IRVINE, Calif. - Inari Medical, Inc. (NASDAQ: NARI), a company specializing in medical devices for venous diseases, has announced encouraging two-year interim results from its CLOUT registry study. The findings were presented at the American Venous Forum by Dr. David Dexter, a vascular surgeon and the study's principal investigator. The results highlight the safety and effectiveness of Inari's ClotTriever system for patients with deep vein thrombosis (DVT).
According to the interim data, the ClotTriever system demonstrated low rates of rethrombosis, with 5.0% at 30 days and 8.4% at six months. Out of the 228 patients who completed the two-year follow-up, only 7.3% experienced moderate to severe post-thrombotic syndrome (PTS), a significant improvement over historical rates from studies such as ATTRACT and CAVA, which reported moderate to severe PTS rates between 18-24%.
The ClotTriever is described as the most utilized and studied thrombectomy device in DVT treatment. Dr. Thomas Tu, Chief Medical Officer at Inari, emphasized the importance of robust clinical data and the company's commitment to establishing the ClotTriever and FlowTriever systems as the standard of care for DVT and pulmonary embolism (PE) patients.
Inari Medical's ongoing efforts also include the DEFIANCE randomized controlled trial, comparing the outcomes of ClotTriever treatment to anticoagulation alone, demonstrating the company's dedication to advancing research in the treatment of venous thromboembolism (VTE).
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.